<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04230889</url>
  </required_header>
  <id_info>
    <org_study_id>BL34</org_study_id>
    <nct_id>NCT04230889</nct_id>
  </id_info>
  <brief_title>Evaluation of Glucose Control in Patients With Diabetes</brief_title>
  <official_title>A Pilot Study to Evaluate Glucose Control in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, multicenter, open-labeled, parallel, three group pilot study to evaluate the&#xD;
      impact of a diabetes-specific nutritional shake on glucose control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2017</start_date>
  <completion_date type="Actual">February 15, 2018</completion_date>
  <primary_completion_date type="Actual">February 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interstitial Glucose Response</measure>
    <time_frame>Study Day 1 to Study Day 14</time_frame>
    <description>Change versus baseline phase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial Glucose</measure>
    <time_frame>Study Day 1 to Study Day 14</time_frame>
    <description>Change in daily total glucose</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Nutrition Behaviors Self-Reported Outcome Questionnaire</measure>
    <time_frame>Study Day 1 to Study Day 14</time_frame>
    <description>15 Likert scale questions related to diet selection, oral nutritional supplement use, cravings and hunger control</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical Activity Questionnaire</measure>
    <time_frame>Study Day 1</time_frame>
    <description>Adapted from National Health Interview Survey; Subject completed; 3 questions related to description of typical physical activity</description>
  </other_outcome>
  <other_outcome>
    <measure>Habitual Snack Timing Questionnaire</measure>
    <time_frame>Study Day 1</time_frame>
    <description>Subject completed; 3 questions related to frequency, timing and reason for snacking</description>
  </other_outcome>
  <other_outcome>
    <measure>Daily Tracking Log</measure>
    <time_frame>Study Day 1 to Study Day 14</time_frame>
    <description>Subject reported log of sleeping, exercise and eating information</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>Study Day 1 to Study Day 14</time_frame>
    <description>Measured in kg</description>
  </other_outcome>
  <other_outcome>
    <measure>Height</measure>
    <time_frame>Study Day 1</time_frame>
    <description>Measured in cm</description>
  </other_outcome>
  <other_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>Study Day 1</time_frame>
    <description>Measured in inches</description>
  </other_outcome>
  <other_outcome>
    <measure>Medications</measure>
    <time_frame>Study Day 1 to Study Day 14</time_frame>
    <description>Subject reported medication usage including dose, unit, frequency and reason for use</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Glycemic Control</condition>
  <arm_group>
    <arm_group_label>Usual Diet Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Instructed to continue to maintain a diet pattern of three main meals (breakfast, lunch and dinner) with two daily snacks including a usual snack (of their own choosing) mid-morning and a usual snack (of their own choosing) mid-afternoon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 Nutritional Shake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Instructed to consume one nutrition shake instead of their usual breakfast and consume the second nutrition shake for their mid-afternoon snack.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Nutritional Shake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Instructed to consume one Study Shake instead of their usual breakfast and the second Study Shake for the second snack before bed-time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Diet Group</intervention_name>
    <description>three main meals and two snacks</description>
    <arm_group_label>Usual Diet Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group 1 Nutritional Shake</intervention_name>
    <description>2 servings per day</description>
    <arm_group_label>Group 1 Nutritional Shake</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group 2 Nutritional Shake</intervention_name>
    <description>2 servings per day</description>
    <arm_group_label>Group 2 Nutritional Shake</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes as evidenced by the use of metformin, thiazolidinones, or&#xD;
             sulfonylureas, alone or in combination, with constant dose for a least 2 months prior&#xD;
             to Screening and is able to maintain medication dose throughout the duration of the&#xD;
             study&#xD;
&#xD;
          -  A1C ≥ 7.0% and ≤ 10.0%&#xD;
&#xD;
          -  Follows a consistent eating pattern of 3 main meals with snacks&#xD;
&#xD;
          -  BMI ≥ 25.0 and ≤ 40.0 kg/m2&#xD;
&#xD;
          -  Stable body weight for the past 2 months prior to Screening Visit&#xD;
&#xD;
          -  If on thyroid medication or hormone replacement therapy, dose been has been constant&#xD;
             for at least 2 months prior to Screening Visit&#xD;
&#xD;
          -  If taking vitamin C supplement &gt;60 mg/d, is willing to discontinue throughout the&#xD;
             duration of the study&#xD;
&#xD;
          -  Willing to take non-aspirin pain relievers through the duration of the study&#xD;
&#xD;
          -  Voluntarily signed and dated an informed consent form (ICF), approved by an&#xD;
             Independent Ethics Committee (IEC)/Institutional Review Board (IRB), and provided&#xD;
             Health Insurance Portability and Accountability Act (HIPAA) (or other applicable&#xD;
             privacy regulation) authorization prior to any participation in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not taking oral anti-hyperglycemic medications (e.g., controlled by diet); is taking&#xD;
             other oral anti-hyperglycemic medications other than metformin, thiazolidinones, or&#xD;
             sulfonylureas; or on injectable medications (e.g., exenatide, insulin) for glucose&#xD;
             control&#xD;
&#xD;
          -  History of diabetic ketoacidosis&#xD;
&#xD;
          -  History of metabolic/endocrine (other than diabetes), hepatic, or significant renal&#xD;
             disease&#xD;
&#xD;
          -  Follows a non-typical eating pattern, such as very low carbohydrate diet, strict&#xD;
             vegetarianism&#xD;
&#xD;
          -  Currently using diabetes-specific nutritional product(s), defined as more than one&#xD;
             eating occasions per week&#xD;
&#xD;
          -  Non-typical or erratic sleep-wake pattern, such as nightshift worker, chronic insomnia&#xD;
&#xD;
          -  Pregnant as confirmed via urine pregnancy test, attempting to conceive or not willing&#xD;
             and able to practice birth control during the study duration (only applicable to&#xD;
             female subjects)&#xD;
&#xD;
          -  Skin lesions, hyperhidrosis, eczema, psoriasis, scarring, tattoos, redness, infection&#xD;
             or edema at the application sites that in the opinion of the study investigator or&#xD;
             study physician could interfere with device placement or the accuracy of interstitial&#xD;
             glucose measurements&#xD;
&#xD;
          -  X-ray, MRI or CT appointment scheduled during the period of study participation, and&#xD;
             the appointment cannot be rescheduled for a time before study participation starts or&#xD;
             after study participation ends&#xD;
&#xD;
          -  Current infection (requiring medication or which might be expected to require&#xD;
             hospitalization); has had inpatient surgery, or corticosteroid treatment (excluding&#xD;
             topical creams) in the last 3 months or antibiotics in the last 3 weeks prior to&#xD;
             Screening Visit&#xD;
&#xD;
          -  Active malignancy, excluding carcinoma in-situ of the cervix, cutaneous malignancies&#xD;
             (basal cell carcinoma, squamous cell carcinoma, except melanoma)&#xD;
&#xD;
          -  Chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis A, B&#xD;
             or C, or HIV&#xD;
&#xD;
          -  History of bariatric surgery including gastric balloon; history of gastrointestinal&#xD;
             disease (e.g., crohns, colitis, celiac) or intestinal surgery that can interfere with&#xD;
             consumption/digestion/absorption of study product&#xD;
&#xD;
          -  Habitually engages in strenuous exercise (e.g., high intensity aerobic exercise;&#xD;
             including heavy physical labor), duration of 1 hour or longer, 3 or more times per&#xD;
             week&#xD;
&#xD;
          -  Known to be allergic or intolerant to any ingredient found in the study products&#xD;
&#xD;
          -  Currently taking any medications, herbals, or dietary supplements, other than allowed&#xD;
             medications, during the past 4 weeks that could profoundly affect (in the opinion of&#xD;
             the PI or study physician) blood glucose or appetite&#xD;
&#xD;
          -  Eating disorder, severe dementia or delirium, history of significant neurological or&#xD;
             psychiatric disorder, alcoholism, substance abuse or other conditions that may&#xD;
             interfere with study product consumption or compliance with study protocol procedures&#xD;
&#xD;
          -  Participant in a concomitant AN trial or trial of a nonregistered drug (or is within&#xD;
             the 30 day follow-up period for such a trial) or that otherwise conflicts with this&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vikkie Mustad, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott Nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MB Clinical Research</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33487</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Clinical Research</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Daibetes and Osteoporosis Center</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Partners Institute, International Diabetes Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

